A group of nearly 40 physicians and public health officials is asking the Food and Drug Administration to change the labeling for certain medications for chronic pain, according to a MedPage Today report.
The group, which argues that opioid labeling is overly broad, is pushing for the FDA to remove the word "moderate" from the description that describes drugs as approved for "moderate to severe pain."
Among those who signed the petition are members of Physicians for Responsible Opioid Prescribing and physicians or researchers with the New York City Health Commissioner, the Cleveland Clinic and the Mayo Clinic.
Nektar Launches Phase 2 Study for Chronic Pain Drug
Relmada Raises $3M to Develop LevoCap Painkiller
The group, which argues that opioid labeling is overly broad, is pushing for the FDA to remove the word "moderate" from the description that describes drugs as approved for "moderate to severe pain."
Among those who signed the petition are members of Physicians for Responsible Opioid Prescribing and physicians or researchers with the New York City Health Commissioner, the Cleveland Clinic and the Mayo Clinic.
Related Articles on Pain Management:
Orexo Seeks FDA Approval for Opioid Dependency DrugNektar Launches Phase 2 Study for Chronic Pain Drug
Relmada Raises $3M to Develop LevoCap Painkiller